Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Eisai Inc. Clear all
Completed Phase 4 Interventional Results available

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

NCT00966277
View directory record Official record
Conditions
Pancreatic Cancer, Venous Thromboembolism
Interventions
Dalteparin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 3 Interventional

Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.

NCT00214552
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux Disease
Interventions
rabeprazole
Drug
Lead sponsor
Associated Scientists to Help Minimize Allergies
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Richland, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Perampanel on Neurophysiology Test Perimeters

NCT03653741
View directory record Official record
Conditions
Healthy
Interventions
Perampanel 6 MG
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 3 Interventional

Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

NCT00165737
View directory record Official record
Conditions
Dementia, Vascular
Interventions
Donepezil Hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
41 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
5
States / cities
Hot Springs, Arkansas • St. Petersburg, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2011 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants

NCT05533801
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lecanemab
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 14, 2026, 10:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

NCT02753595
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants

NCT04023877
View directory record Official record
Conditions
Dementias With Lewy Bodies
Interventions
E2027
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 14, 2026, 10:02 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

NCT00754052
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
11 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)

NCT00967499
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Ondansetron, Palonosetron
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Phoenix, Arizona • Laguna Hills, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

Trial of Decitabine in Patients With Acute Myeloid Leukemia

NCT00260832
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine or Supportive Care, Dacogen (decitabine) only
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
65 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
37
States / cities
Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

NCT00154063
View directory record Official record
Conditions
Migraine Prophylaxis
Interventions
E2007, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Oceanside, California • Santa Monica, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

NCT01328249
View directory record Official record
Conditions
HER2-normal
Interventions
eribulin mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Lebanon, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

NCT01104155
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
eribulin mesylate + erlotinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
50
States / cities
Bessemer, Alabama • Birmingham, Alabama • Beverly Hills, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 14, 2026, 10:02 PM EDT
Terminated Phase 4 Interventional Results available

Fycompa in Catamenial Epilepsy

NCT05201703
View directory record Official record
Conditions
Catamenial Epilepsy
Interventions
Fycompa, Fycompa with a boost
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

NCT00398983
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Early Phase 1 Interventional Results available

A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

NCT00718770
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Bexarotene
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

NCT02998775
View directory record Official record
Conditions
Hepatic Impairment; Renal Impairment
Interventions
Plasma Sampling
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 14, 2026, 10:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

NCT03552107
View directory record Official record
Conditions
Obesity, Weight Loss, Overweight
Interventions
Lorcaserin
Drug
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 14, 2026, 10:02 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Oral E1018 in Healthy Adult Participants

NCT06854042
View directory record Official record
Conditions
Malaria, Healthy Participants
Interventions
E1018, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 1 Interventional

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

NCT03430518
View directory record Official record
Conditions
HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer
Interventions
Durvalumab, Eribulin
Drug
Lead sponsor
Amy Tiersten
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

NCT02952820
View directory record Official record
Conditions
Insomnia Disorder
Interventions
lemborexant, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
42
States / cities
Chandler, Arizona • Rogers, Arkansas • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 3 Interventional Results available

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

NCT00395135
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg BID, Matching Placebo BID
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 14, 2026, 10:02 PM EDT
Not yet recruiting No phase listed Observational

A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease

NCT07864623
View directory record Official record
Conditions
Alzheimers Disease
Interventions
No Intervention
Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

NCT01136733
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 14, 2026, 10:02 PM EDT